107 results about "Hematological Tumor" patented technology

The invention discloses a blood tumor patient clinical data analysis method and system based on a knowledge graph, and relates to the technical field of medical information processing. The method comprises the following steps: analyzing an unstructured text by utilizing a natural language processing model, and constructing a standardized entity set; aggregating laboratory indexes through a dynamic window, and constructing a time axis data set for marking a treatment stage; a standardized entity is integrated based on a blood tumor ontology model, a dynamic global knowledge graph is constructed in combination with a clinical causal relationship and a time sequence path, and chain reaction early warning is realized; based on the real-time patient sub-atlas, successful cases with the same molecular features are retrieved in the knowledge atlas to generate a candidate treatment scheme set, a graph neural network trained through an optimization algorithm is utilized to predict the complication risk of each scheme, and finally the optimal treatment scheme is evaluated and selected; according to the method, a clinical data barrier is broken through, dynamic reasoning, advanced risk early warning and personalized scheme optimization of the whole treatment cycle are realized, and the diagnosis and treatment accuracy, safety and medical resource utilization efficiency are remarkably improved.

The invention provides a hematologic tumor cord blood transplantation treatment prognosis risk assessment method and system based on multi-modal data fusion, a medium and electronic equipment, and relates to the technical field of medical artificial intelligence and clinical decision support systems. The method comprises the following steps: acquiring multi-modal data including unit characteristic data of cord blood of a patient, biomarker data and the like; screening out a simplified feature set from the preprocessed multi-modal data; fusing the simplified features based on three complementary strategies of feature level direct cascade, knowledge graph semantic association and multi-model decision integration; and a prediction model is constructed, and a standardized risk assessment report is generated based on the optimized hierarchical risk levels and is used for assisting clinical decision support. According to the method, accurate layering of the prognosis risk of the hematologic tumor umbilical cord blood transplantation patient is achieved, high-accuracy risk prediction is provided, good interpretability and personalized decision support capacity are achieved, and a scientific basis is provided for clinical practice.

The invention relates to the technical field of disease curative effect evaluation, and discloses a method for evaluating the curative effect of granulocyte deficiency accompanying fever after hematologic tumor chemotherapy based on machine learning, and the method comprises the steps: S1, collecting and preprocessing multi-center medical data, the data comprising structured clinical data and multi-modal unstructured data; s2, a curative effect prediction model is constructed based on a graph neural network, and a central moment constraint-based graph federal learning training model is adopted, wherein a patient graph is constructed as an original graph and an enhanced graph is generated; respectively processing the original image and the enhanced image through a two-channel image convolutional neural network, and extracting a high-order representation vector; constructing an enhanced perception loss function based on the high-order representation vectors of the original image and the enhanced image; combining a federated learning framework with multi-center data to train a model; and S3, predicting a curative effect evaluation result through the trained curative effect prediction model. The accuracy, the stability and the clinical interpretability of curative effect evaluation are improved.

Systems and methods for determining a blood tumor mutational burden (bTMB) for a test subject are provided in which there is obtained, from a panel-enriched sequencing reaction, a plurality of nucleic acid sequences. The plurality of nucleic acid sequences comprises a corresponding sequence for each cell-free DNA fragment in a plurality of cell-free DNA fragments obtained from a liquid biopsy sample from the test subject. Each respective cell-free DNA fragment in the plurality of cell-free DNA fragments corresponds to a respective probe sequence in a plurality of probe sequences used to enrich cell-free DNA fragments in the liquid biopsy sample in the panel-enriched sequencing reaction. There is determined, using the panel-enriched sequencing reaction, that a circulating tumor fraction (ctFE) is above a threshold ctFE value. Responsive to this determination, the bTMB is calculated for the test subject from the panel-enriched sequencing reaction and reported.

The invention belongs to the technical field of biomedical detection, and discloses a Raman spectrum analysis device for quantitative detection of hematologic tumor markers, which comprises a blood collection centrifugal unit with a self-adaptive load regulation mechanism for monitoring blood density and components in real time, centrifugal force and time parameters are automatically adjusted according to the blood density and components; the optical fiber Raman spectrometer is provided with an automatic wavelength calibration system, and an ultrafast laser pulse transmitter and a high-sensitivity photon counting detector are integrated on the optical fiber Raman spectrometer. Raman scattering signals are enhanced by adopting a quantum entanglement light source and a nonlinear optical crystal; according to the invention, the detection capability on low-concentration tumor markers can be obviously improved. Due to the improvement, the device can accurately detect the existence of the tumor marker at the early stage of cancer, and powerful support is provided for early treatment of a patient.

The invention discloses a hematologic tumor calming treatment and protection intervention method based on potential profile analysis, and relates to the technical field of medical treatment and health information analysis, and the method comprises the following steps: S1, constructing a multi-dimensional intervention feature data set; s2, constructing a profile analysis model according to the feature data set; s3, performing category stability verification according to a section analysis result; s4, screening an intervention reference template according to a stability verification result; s5, matching individual features according to the intervention reference template to form a preset intervention path; s6, constructing a profile-driven path execution and feedback control system by using an intervention preset path; by setting a profile response function modeling model and combining a multi-intervention feature matrix to construct a high-resolution profile function, the problem that an existing profile division model is insufficient in continuous variable processing capacity is effectively solved, the profile structure expression capacity and individual heterogeneity description precision are improved, and the profile division efficiency is improved. The method is suitable for the fine layered modeling requirement under the driving of multi-dimensional intervention features.

The invention belongs to the technical field of biological medicine, and particularly relates to a culture method and application of a hematological malignant tumor organoid. The culture method comprises the following steps: S01, obtaining a tumor cell sample; s02, preparing a bone marrow microenvironment simulation matrix, and resuspending tumor cells; s03, a specific culture medium is added for hematoma organoid culture; s04, performing phenotype identification on the cultured hematological malignant tumor organoid; and hematological malignant tumor organs with phenotypes close to those of bone marrow cells of the patient are screened out. According to the method system disclosed by the invention, the hematoma organoid is successfully cultured and is further subjected to phenotype identification, and the screened hematoma organoid is close to the cellular immune phenotype of a patient and can be used for accurate detection of clinical patient drug sensitivity and effective test of potential effective target drugs.

The invention provides a human interleukin 2-polyethylene glycol conjugate and use thereof. The human interleukin 2-polyethylene glycol conjugate provided by the invention comprises a recombinant human interleukin 2 containing at least one unnatural amino acid and PEG coupled to the at least one unnatural amino acid. The unnatural amino acid is a compound containing a carbonyl terminal group and having a structure as shown in formula (I) or an enantiomer thereof, and the PEG is coupled to the at least one unnatural amino acid by forming an oxime bond between the carbonyl terminal group and the PEG containing a hydroxylamine terminal group. The human interleukin 2-polyethylene glycol conjugate provided by the invention can be used individually or in combination with other anti-tumor drugs for the treatment of diseases such as solid tumors and hematologic tumors.

The invention relates to the technical field of biological detection, in particular to a biomarker for predicting or diagnosing a Selanisol inhibitor and application of the biomarker. The invention relates to an application of a substance for detecting the expression quantity of a gene. The application comprises an application in a product for predicting or diagnosing the drug resistance of Selanisole, an application in a product for screening or preparing a cancer targeted drug, and an application in a product for predicting the prognosis of a cancer patient. The invention also provides a pharmaceutical composition for treating the drug resistance of the Selanisole. Aiming at the drug resistance of the XPO1 inhibitor, the invention provides a brand new prediction, diagnosis and treatment method.

The invention relates to the field of medical auxiliary instruments, in particular to a hematologic tumor sample transfer box which comprises a box body, a partition plate capable of sliding up and down is arranged in the box body, a fixing assembly is arranged in the box body, and the fixing assembly comprises a first fixing frame, a second fixing frame and a connecting piece which are fixed to the bottom wall in the box body. The first fixing frame is used for limiting one side of the test tube rack; the second fixing frame is arranged in the box body and can slide horizontally; the second fixing frame corresponds to the first fixing frame and is used for limiting the other side of the test tube rack; a connecting piece is arranged between the partition plate and the second fixing frame, and when the partition plate slides upwards, the connecting piece pulls the second fixing frame back into the box body. A springback piece is arranged on one side of the second fixing frame, and when the partition plate resets downwards, the springback piece pops out the second fixing frame; the test tube rack for placing test tube samples can be integrally transferred into the box body and can be automatically locked, so that not only can quick transfer be realized, but also collision damage in the transfer process can be avoided.

Disclosed are Schistosoma japonicum eggs and the ingredients of secretions and excretions thereof, comprising eggs, egg culture supernatant, and egg secreted proteins. (hereinafter referred to as “Schistosoma eggs and secretions and excretions thereof” for short). A Schistosoma infection can significantly inhibit metastatic tumors of organs such as lungs, and an anti-tumor effect is mediated by the “Schistosoma eggs and secretions and excretions thereof”, which have the effect of inhibiting various host tumors, comprising lung cancer, liver cancer, melanoma, and hematological tumors. Two egg secreted proteins having an anti-tumor effect are further identified. The “Schistosoma eggs and secretions and excretions thereof” exert an anti-tumor effect by activating natural immunity such as alveolar macrophages. The “Schistosoma eggs and secretions and excretions thereof” have a potential application value in prevention and treatment of tumors in humans.

The invention discloses a hematologic tumor diagnosis and treatment primer group, a kit and application. The primer group comprises a first primer group and / or a second primer group, the first primer group is used for amplifying IGH, IGDH, IGK and IGL; the first primer group is used for amplifying TRB V-J, TRB D-J, TRG and TRD, the second primer group is used for amplifying TRB V-J, TRB D-J, TRG and TRD, after the primer groups amplify and rearrange sequences, the positive detection of clinical samples can be remarkably improved, the obtained CDR3 sequence can be used for clinical monitoring and can independently evaluate an immune group library of each patient, the immune state of an individual can be accurately reflected, the change condition of tumor cells of the patient can be dynamically monitored, and the clinical detection efficiency can be improved. And the method has good reliability and repeatability.

The present disclosure provides a group of aromatic (e.g., pyridinyl, pyrimidinyl, pyrazinyl, or phenyl) diamidine analogs and pharmaceutically acceptable salts that are useful for treating a proliferative disease. The proliferative disease may include solid cancer or blood cancer. Compositions, methods of synthesizing the same and methods for treating various cancer using the analogs are disclosed herein. The present disclosure also provides pharmaceutical formulations comprising at least one of the compounds with a pharmaceutically acceptable carrier, diluent or excipient therefor.

The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.

The invention relates to the technical field of image recognition, and particularly discloses an auxiliary blood tumor pathological diagnosis system and method based on artificial intelligence, and the system extracts a pathological image group of a patient through a pathological diagnosis auxiliary platform, analyzes the data of each pathological image, and judges the effective feature value of each pathological image; the effective feature values of the pathological images are compared with a predefined effective feature threshold value to obtain a comparison result, and the pathological diagnosis auxiliary platform judges whether the effective features of the pathological images are enhanced or not based on the comparison result; and extracting cell characteristic data in each pathological image according to each pathological image, judging the characteristic complexity of each pathological image, and performing difference analysis on the pathological image group to complete auxiliary blood tumor pathological diagnosis.

The invention relates to the technical field of biological medicine, in particular to an NK cell and application of the NK cell in tumor treatment medicines.The NK cell is prepared through the following method that a, an anti-PD-L1 antibody with the concentration being 20-35 micrograms / mL is used for pretreating a human peripheral blood mononuclear cell; b, in a container coated with the anti-CD16 antibody, a culture medium containing Galunissertib is used for culture, and the concentration of the Galunissertib is 4-6 [mu] M; and step c, transforming and expressing an F158V mutant CD16a receptor of UniProt P08637 through gene engineering. According to the technical scheme, a systematic solution is provided for NK cell therapy of a targeted tumor microenvironment, and wider clinical application in treatment of solid tumors and hematological tumors is expected to be achieved.

The present invention relates to therapeutic treatment of cancer, particularly solid and hematological tumors, with combination therapy using PM14 and a topoisomerase I inhibitor.

The present disclosure provides methods and systems for genomic data representation and estimation of various biomarkers of interest in personalized medicine and particularly in cancer genomics such as molecular residual disease (MRD), tumor fraction (TF), blood tumor mutational burden (bTMB) and clonal hematopoiesis of indeterminate potential (ChIP).

The present invention provides a method and system for early screening of hematologic malignancies based on multi-channel blood scattergrams. The method comprises: obtaining a blood scattergram of a target subject; inputting each of the blood scattergrams into a pre-constructed feature extraction network to obtain deep feature maps output by the feature extraction network corresponding to each of the blood scattergrams; inputting each of the obtained deep feature maps into a pre-trained balanced optimization model to obtain an enhanced feature map output by the balanced optimization model; inputting each of the enhanced feature maps into a pre-trained classifier to obtain a category prediction result output by the classifier; fusing each of the enhanced feature maps to obtain a fused feature map, and obtaining a fused feature category prediction result based on the fused feature map, and obtaining a final category prediction result through weighted calculation. This method implements computer-assisted screening, reduces the empirical dependence of early screening for hematologic malignancies, and improves the accuracy and efficiency of screening results.

The invention provides an extraction method of high-performance gamma delta T immune cells and application of the high-performance gamma delta T immune cells in tumors. The method comprises the following steps: firstly, separating mononuclear cells from peripheral blood, carrying out activation induction by using a serum-free culture medium containing zoledronic acid, IL-15 and OKT3, and supplementing a culture medium containing IL-2 according to a specific proportion for multiplication culture from the third day of culture. Through the optimization process, the expression rate of TCR-gamma delta < + > is as high as 96.84%, and gamma delta T cells with high activity are obtained. An in-vivo tumor inhibition experiment shows that the cell has a remarkable growth inhibition effect on liver cancer nude mouse transplanted tumor, the effect is equivalent to that of a positive control drug, and obvious toxic and side effects are not observed. The method is stable in process and clear in component, and a reliable technical basis is provided for clinical transformation of gamma delta T cells in immunotherapy of solid tumors and hematologic tumors.

This invention belongs to the fields of medicinal chemistry and pharmaceutical technology, and relates to 1,4-benzodiazepines and their use in the preparation of antitumor drugs, specifically the use of 1,4-benzodiazepines in the preparation of annexin A3 (ANXA3) degrading agents and in the preparation of drugs for treating cancer. In particular, it discloses the use of 1,4-benzodiazepines, or pharmaceutically acceptable salts thereof, or stereoisomers thereof, or compositions of drugs with these as active ingredients, in the preparation of drugs for the prevention and treatment of tumors. These compounds can bind to the ANXA3 protein, induce ANXA3 protein degradation, inhibit the proliferation, cloning, migration, and invasion of tumor cells, and exert antitumor therapeutic effects in vivo. They can be used to treat solid tumors and hematological malignancies, including breast cancer, cervical cancer, ovarian cancer, colorectal cancer, gastric cancer, pancreatic cancer, lung cancer, esophageal cancer, liver cancer, leukemia, and melanoma.

The present application relates to the technical field of medical devices, in particular to a wound debridement device for blood tumor patients, comprising a handle vertically arranged, an injection part, an adsorption part and a mounting part for clamping medical cotton, the lower end of the handle is provided with a placing cavity, the mounting part is arranged in the placing cavity, the injection part comprises a first cylindrical cavity, a first button, a vertical slide and a first flow channel arranged in the handle, the mounting part comprises a fixing block arranged in the placing cavity and detachably connected with the handle, when the medical cotton is clamped on the handle by the fixing block, part of the medical cotton extends out of the lower end of the handle through the center hole of the fixing block, and the adsorption part comprises a second cylindrical cavity, a second button and an adsorption channel arranged vertically. The present application is simple and fast in operation when debriding the wound of the patient, greatly shortens the debridement time and reduces the labor intensity of medical staff, simultaneously reduces the time of exposing the wound of the patient to the outside, reduces the risk of wound infection and improves the wound healing speed.

Disclosed are compositions and methods for targeted treatment of cancer, such as hematologic cancer. In particular, chimeric antigen receptor (CAR) T cells are disclosed that can be used with adoptive cell transfer to target and kill cancer cells with reduced antigen escape. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with hematologic cancer that involves adoptive transfer of the disclosed CAR T cells.

1. Name of the Design Product: Blood Tumor Cell Separator. 2. Use of the Design Product: This design product is used to separate and enrich tumor cells in human peripheral circulating blood. 3. Design Key Points of the Design Product: Lies in the shape. 4. Picture or Photograph that Best Illustrates the Design Key Points: Perspective view.

The present invention discloses a clinical data analysis method and system for hematological tumor patients based on knowledge graphs, which relates to the field of medical information processing technology. The present invention utilizes a natural language processing model to parse unstructured text and construct a standardized entity set. Laboratory indicators are aggregated through dynamic windows to construct a timeline data set annotated with treatment stages. Standardized entities are integrated based on a hematological tumor ontology model, and a dynamic global knowledge graph is constructed in combination with clinical causal relationships and temporal paths to achieve chain reaction warnings. Based on real-time patient subgraphs, successful cases with the same molecular characteristics are retrieved in the knowledge graph to generate a set of candidate treatment plans, and a graph neural network trained with an optimized algorithm is used to predict the risk of complications of each plan, and finally the optimal treatment plan is evaluated and selected. The present invention breaks through the barriers of clinical data, realizes dynamic reasoning, advanced risk warning and personalized plan optimization throughout the treatment cycle, and significantly improves the accuracy, safety and efficiency of medical resource utilization in diagnosis and treatment.

The application provides a novel DNA methylation marker TAGMe-5 for tumor identification and use thereof. The tumor marker TAGMe-5 of the application shows significant DNA methylation difference between cancer adjacent tissue and cancer tissue, and the difference has significant statistical significance, and the difference is shown in numerous tumors such as solid tumors and non-solid tumors. The solid tumors include lung cancer, liver cancer, prostate cancer, cervical cancer, endometrial cancer, urothelial carcinoma, biliary tract tumor, etc. The non-solid tumors include hematological tumors, lymphoma, etc. Therefore, the tumor marker of the application can be used for clinical screening of pan-cancer, molecular diagnosis, prognosis and efficacy evaluation.

To provide compositions and methods for treatment of hematological tumors with engineered or non-engineered γδ-T cells.SOLUTION: In some embodiments, γδ-T cells comprise a chimeric antigen receptor (CAR) construct. The CAR construct can contain an anti-CD20 binding domain or anti-B cell maturation antigen (BCMA) binding domain, a CD8 hinge and transmembrane domain, a costimulatory domain, a CD3ζ signalling domain, a combination thereof, or all thereof. The CAR construct can contain a domain encoding for a secreted common gamma chain cytokine such as an sIL15 domain.SELECTED DRAWING: None

Provided herein are CD70-binding proteins comprising a CD70-binding domain and a transmembrane domain, engineered immune cells comprising the CD70-binding proteins, and methods of making and using the same. Also provided herein are engineered immune cells e.g. CAR (chimeric antigen receptor) T cells for administration to patients to treat cancer (e.g., solid tumors and hematologic tumors) and other unwanted conditions. The cells are engineered to functionally express a first antigen binding molecule e.g. a CD70 CAR and a second antigen binding molecule e.g. a second CAR that binds a target molecule characteristic of the cancer or other disease or unwanted condition. The cells may be further engineered to reduce the functional expression level of one or more of TRAC, CD52 and CD70. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering them.

The invention relates to the technical field of medical image processing, in particular to a blood disease classification-oriented bone marrow cell multi-scale identification method, which comprises the following steps of: constructing and training a bone marrow cell identification model, and inputting an image to be identified into the trained bone marrow cell identification model to obtain an identification result; the bone marrow cell recognition model comprises a hierarchical feature extraction module, a feature enhancement module, a class center learning framework module and a multi-layer perceptron; compared with an existing model, the classification number and accuracy of cell classification are improved, preliminary diagnosis of hematologic tumor diseases can be achieved in an auxiliary mode, and the examination time is shortened.

The application provides a CAR-T cell therapy toxicity management optimization method and system, relates to the technical field of artificial intelligence, and comprises the following steps: acquiring clinical data of a blood tumor patient receiving a CAR-T cell therapy; performing missing value interpolation and standardization processing on baseline characteristic information and process monitoring data to obtain a standardized data set; obtaining a calibrated virtual patient physiological model according to a preset tumor cell kinetics model, an immune cell kinetics model and a toxicity reaction model; taking the calibrated virtual patient physiological model as an interactive environment to obtain a correlation database; constructing a deep Q network intelligent agent with a maximum reward function as a target to obtain an optimized deep Q network intelligent agent; and inputting the process monitoring data into the optimized deep Q network intelligent agent to obtain a target strategy, so that the individualized CAR-T treatment strategy balancing the therapeutic effect and toxicity can be automatically output by inputting the real-time monitoring data of the patient.